These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24772915)

  • 1. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
    Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
    Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
    Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
    Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N
    Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
    de la Cruz-Hernández E; Pérez-Cárdenas E; Contreras-Paredes A; Cantú D; Mohar A; Lizano M; Dueñas-González A
    Virol J; 2007 Feb; 4():18. PubMed ID: 17324262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
    De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
    Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
    Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
    PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
    Chavez-Blanco A; Perez-Plasencia C; Perez-Cardenas E; Carrasco-Legleu C; Rangel-Lopez E; Segura-Pacheco B; Taja-Chayeb L; Trejo-Becerril C; Gonzalez-Fierro A; Candelaria M; Cabrera G; Duenas-Gonzalez A
    Cancer Cell Int; 2006 Jan; 6():2. PubMed ID: 16448574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer.
    Candelaria M; Cetina L; Pérez-Cárdenas E; de la Cruz-Hernández E; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Chanona J; Arias D; Dueñas-González A
    Eur J Gynaecol Oncol; 2010; 31(4):386-91. PubMed ID: 20882878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
    Shoji M; Ninomiya I; Makino I; Kinoshita J; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Kitagawa H; Fushida S; Harada S; Fujimura T; Ohta T
    Int J Oncol; 2012 Jun; 40(6):2140-6. PubMed ID: 22469995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
    Coronel J; Cetina L; Pacheco I; Trejo-Becerril C; González-Fierro A; de la Cruz-Hernandez E; Perez-Cardenas E; Taja-Chayeb L; Arias-Bofill D; Candelaria M; Vidal S; Dueñas-González A
    Med Oncol; 2011 Dec; 28 Suppl 1():S540-6. PubMed ID: 20931299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
    Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
    Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments.
    Harikrishnan KN; Karagiannis TC; Chow MZ; El-Osta A
    Cell Cycle; 2008 Feb; 7(4):468-76. PubMed ID: 18239454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
    Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
    Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
    Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
    Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of DNA Methyltransferase in Comparison to and in Combination with Histone Deacetylase Inhibitors on Hepatocellular Carcinoma HepG2 Cell Line.
    Sanaei M; Kavoosi F
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1119-1125. PubMed ID: 31030484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
    Kumanishi S; Yamanegi K; Nishiura H; Fujihara Y; Kobayashi K; Nakasho K; Futani H; Yoshiya S
    Int J Oncol; 2019 Jul; 55(1):167-178. PubMed ID: 31180533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective and new potent drug combination: Histone deacetylase and Wnt/β-catenin pathway inhibitors in lung carcinoma cells.
    Akgun O; Erkisa M; Ari F
    J Cell Biochem; 2019 Sep; 120(9):15467-15482. PubMed ID: 31037769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
    Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
    Ann Hematol; 2017 Nov; 96(11):1825-1832. PubMed ID: 28831600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.
    Mora-García Mde L; Duenas-González A; Hernández-Montes J; De la Cruz-Hernández E; Pérez-Cárdenas E; Weiss-Steider B; Santiago-Osorio E; Ortíz-Navarrete VF; Rosales VH; Cantú D; Lizano-Soberón M; Rojo-Aguilar MP; Monroy-García A
    J Transl Med; 2006 Dec; 4():55. PubMed ID: 17192185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epigenetic modifier, valproic acid, enhances radiation sensitivity.
    Karagiannis TC; Kn H; El-Osta A
    Epigenetics; 2006; 1(3):131-7. PubMed ID: 17965607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.